Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient

Abstract

An agent for preventing and/or treating Parkinson's disease or Parkinson's syndrome, comprising, as an active ingredient, an astrocyte function-improving agent is disclosed. The astrocyte function-improving agent is preferably a compound represented by formula (I), a non-toxic salt thereof, or a hydrate thereof: R 5 , R 6 , R 11 and n are defined in the specification.

1 - 7 . (canceled)  
   
   
       8 . A method for increasing the content of dopamine in a brain, which comprises administering to a subject in need thereof an effective amount of (R)-2-propylactanoic acid, a non-toxic salt thereof, or a hydrate thereof.  
   
   
       9 . The method according to  claim 8 , wherein the subject is a patient in which the content of dop amine in the brain is reduced.  
   
   
       10 . The method according to  claim 8 , wherein the subject is a patient with Parkinson's disease or Parkinson's syndrome.  
   
   
       11 . The method according to  claim 10 , wherein the Parkinson's syndrome is tremor, akinesia or rigidity.